Flurry of Funding Drives Toralgen, Other Startups

For people with Type 1 diabetes, a life free from injections and 24/7 monitoring of their blood glucose levels may seem only a fantasy, but an Indianapolis-based biotech company believes relief could come in pill form.

Toralgen Inc. is developing a drug delivery technology it says can take existing drugs that have to be injected and transform them into oral medications.  


About Toralgen, Inc.
Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Its poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized drug delivery. Toralgen is currently studying treatments for diabetes and autoimmune disorders. For information or to inquire about possible collaborations, visit our website.

Contact: Dave Moore, Toralgen, dnmoore@toralgen.com